Last updated: 07/31/2020 01:00:06

Assessment of any potential retinal effects of Tafenoquine (TQ)

GSK study ID
201807
See study documents
Clinicaltrials.gov ID
NCT02658435
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers
Trial description: The study aims to provide evidence of retinal safety to support the use of tafenoquine as a potential single dose radical cure treatment for patients with Plasmodium vivax (P. vivax) malaria (i.e., co-administration of a schizonticidal drug with TQ). The study will be conducted as a single masked, randomized, placebo-controlled, parallel group design. It will assess retinal changes from baseline using spectral domain optical coherence tomography (OCT) and fundus auto fluorescence (FAF) at Month 3 (90 days) post-dose in adult healthy volunteers (participants). A placebo control group will be used to compare the results in the TQ group. Interim analysis will be conducted after completing 100 out of 300 participants in TQ group and 50 out of 150 participants in matched placebo.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:

Proportion of participants in the TQ group having retinal changes from Baseline in Central subfield thickness and Central retinal lesion thickness

Timeframe: Baseline and Day 90(follow-up)

Proportion of participants in the TQ group having retinal changes from Baseline in Total macular volume

Timeframe: Baseline and Day 90(follow-up)

Proportion of participants in the TQ group having retinal changes from Baseline in Ellipsoid zone disruption

Timeframe: Baseline and Day 90(follow-up)

Proportion of participants in the TQ group having retinal changes from Baseline in abnormal auto-fluorescence patterns

Timeframe: Baseline and Day 90(follow-up)

Secondary outcomes:

Mean change from baseline in OCT parameter like central retinal thickness as a safety measure

Timeframe: Baseline and Day 90(follow-up)

Mean change from baseline in OCT parameter like central subfield thickness as a safety measure.

Timeframe: Baseline and Day 90(follow-up)

Mean change from baseline in OCT parameter like central retinal lesion thickness as a safety measure.

Timeframe: Baseline and Day 90(follow-up)

Mean change from baseline in OCT parameters;. Total macular volume as a safety measure.

Timeframe: Baseline and Day 90(follow-up)

Mean change from baseline in OCT parameters ;. Ellipsoid zone disruption as a safety measure.

Timeframe: Baseline and Day 90(follow-up)

Changes from baseline in the status of the outer retina/photoreceptor complex as a safety measure.

Timeframe: Baseline and Day 90(follow-up)

Proportion of participants with abnormal changes from baseline observed on FAF as a safety measure.

Timeframe: Baseline and Day 90(follow-up)

Mean change from baseline in best corrected visual acuity (BCVA) as a safety measure of TQ in comparison to placebo.

Timeframe: Baseline and Day 90(follow-up)

Proportion of participants with vortex keratopathy from the slit lamp examination as a safety measure of TQ in comparison to placebo.

Timeframe: Baseline and Day 90(follow-up)

Number of participants with of adverse events as a safety measure

Timeframe: 90 days

Interventions:
  • Drug: Tafenoquine 150 mg
  • Drug: Matched placebo 150mg
    • Enrollment:
    486
    Primary completion date:
    2017-14-09
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Ackert, Mohamed, Slakter, El-Harazi, Berni, Gevorkyan, Hardaker, Hussaini, Jones, Koh, Patel, Rasmussen, Barañano, Thompson, Warren, Sergott, Tonkyn, Wolstenholm, Coleman, Yaun, Duparc, Green .RANDOMIZED PLACEBO-CONTROLLED TRIAL EVALUATING THE OPHTHALMIC SAFETY OF SINGLE-DOSE TAFENOQUINE IN HEALTHY VOLUNTEERS.Drug Saf.2019;42(9):1103-1114 DOI: 10.1007/s40264-019-00839-w PMID: 31187437
    Medical condition
    Malaria, Vivax
    Product
    tafenoquine
    Collaborators
    Medicines for Malaria Venture
    Study date(s)
    February 2016 to September 2017
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 45 years
    Accepts healthy volunteers
    Yes
    • Between 18 and 45 years of age inclusive, at the time of signing the informed consent.
    • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, brief physical examination, and laboratory tests.
    • Alanine Aminotransferase (ALT) and bilirubin >1.5 times Upper Limit of Normal (ULN) (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Between 18 and 45 years of age inclusive, at the time of signing the informed consent.
    • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, brief physical examination, and laboratory tests.
    • Participant values for haematology and chemistry within the normal range. A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
    • Body weight between >=35 kilogram (kg) and =<100kg
    • Male OR Female. Female participant is eligible to participate if she is not pregnant (as confirmed by a negative [serum or urine, according to site standard] human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: Non-reproductive potential defined as Pre-menopausal females with one of the following: Documented tubal ligation or Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion or Hysterectomy or Documented Bilateral Oophorectomy or Postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to site specific laboratory reference ranges for confirmatory levels). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from screening until completion of the Day 90 follow-up visit.
    • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
    Exclusion criteria:
    • Alanine Aminotransferase (ALT) and bilirubin >1.5 times Upper Limit of Normal (ULN) (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
    • The QT interval corrected (QTc) for heart rate according to Fridericia’s formula (QTcF). QTcF > 450 milli second (msec). Other calculation methods (e.g. QT interval corrected for heart rate according to Bazett's formula [QTcB], individually corrected QT interval [QTcI]) machine-read or manually over-read are not acceptable.
    • Use of prescription (except female contraception and acetaminophen at doses of =<2 grams(g)/day) or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise participant safety.
    • History of regular alcohol consumption within 30 days of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 millilitre [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
    • Positive results for drugs of abuse
    • Cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 30 days prior to screening.
    • History of sensitivity to TQ, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
    • History of thalassaemia; or current or past history of methemoglobinemia or methemoglobin percentage above the reference range at screening.
    • Lactating females.
    • Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. A positive pre-study drug/alcohol screen.
    • A positive test for human immunodeficiency virus (HIV) antibody.
    • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 15 days of dosing with TQ or matched-placebo.
    • The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
    • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
    • Participants with a hemoglobin values outside the lower limit of normal range. A single repeat is allowed for eligibility determination.
    • Documented phenotypic Glucose-6-phosphate dehydrogenase (G6PD) deficiency, determined by a quantitative assay of enzyme activity. Defined as <70% of locally defined median.
    • A BCVA (bilateral) at screening of =<72 letters
    • Eye disease that could compromise assessment of BCVA or imaging of the posterior pole by fundus photography, or spectral domain OCT, FAF, or is likely to require intervention during the 4 month (approximately) study participation (e.g. cataract, glaucoma with documented visual field loss, ischemic optic neuropathy, retinitis pigmentosa)
    • History of retinal vascular disease, retinal detachment, inflammatory disease, central serous chorioretinopathy, or other retinal disease that may affect posterior retinal function or architecture.
    • Vitreo-retinal interface disorders (e.g. epiretinal membrane, vitreo-macular traction) that may affect posterior retinal function or architecture
    • Intraocular surgery within 3 months of dosing
    • Laser photocoagulation within 3 months of dosing
    • High Myopia (defined as equal to, or worse than, -6.00 diopters)
    • Anterior, intermediate or posterior uveitis (active or history of) or history of significant intraocular infectious disease (e.g., conjunctivitis is not acceptable to include) or another active inflammatory disease
    • An OCT central subfield thickness <250 microns or >290 microns
    • Presence of significant abnormal patterns on FAF or ocular abnormalities on fundus photography at screening.
    • Uncontrolled intraocular pressure >22millimetre of mercury (mmHg).

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Baltimore, Maryland, United States, 21225
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Glendale, California, United States, 91206
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Overland Park, Kansas, United States, 66211
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)
    Statistical analysis plan
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2017-14-09
    Actual study completion date
    2017-14-09

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website